ACE抑制剂和血管紧张素受体阻滞剂（ARBs）可能增加罹患COVID-19的风险

2020-03-24 Allan MedSci原创

近日，一项发表在《Journal of Travel Medicine》之上的研究指出，ACE抑制剂和血管紧张素受体阻滞剂（ARBs）的使用可能增加罹患COVID-19的风险。

近日，一项发表在《Journal of Travel Medicine》之上的研究指出，ACE抑制剂和血管紧张素受体阻滞剂（ARBs）的使用可能增加罹患COVID-19的风险，也解释了为什么患有基础病的老年人会更容易被病毒感染并出现严重肺部并发症。

新型冠状病毒通过与患者下呼吸道ACE2受体结合而引起COVID-19。病毒性肺炎和可能致命的呼吸衰竭可能会在10至14天后发生。

通常，血管紧张素转换酶抑制剂（ACEIs）和血管紧张素受体阻滞剂（ARBs）被推荐用于治疗患有心脏病和高血压患者，也被推荐用于治疗糖尿病和慢性肾脏病相关的心血管疾病。但是，实验模型的研究表明，静脉内注射ACE抑制剂后，心肺循环中ACE2受体的数量增加。由于接受ACEI和ARB治疗的患者肺中与冠状病毒S蛋白结合的ACE2受体数量增加，这些患有心脏疾病的患者被新型冠状病毒感染的风险也随之增加。

原始出处：

https://www.firstwordpharma.com/node/1710231

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (8)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=2085838, encodeId=6f3f2085838f2, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Aug 03 18:25:18 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656005, encodeId=251a16560051c, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Jun 18 05:25:18 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852309, encodeId=5822185230916, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Sep 17 14:25:18 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995210, encodeId=1f65199521099, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Aug 02 17:25:18 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460174, encodeId=623714601e45a, content=<a href='/topic/show?id=34442e21d6' target=_blank style='color:#2F92EE;'>#ARBs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2721, encryptionId=34442e21d6, topicName=ARBs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b56256828, createdName=redcrab, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514758, encodeId=5fc71514e589a, content=<a href='/topic/show?id=ac3489e555e' target=_blank style='color:#2F92EE;'>#血管紧张素受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89755, encryptionId=ac3489e555e, topicName=血管紧张素受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56ce10676101, createdName=1249894fm76暂无昵称, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587538, encodeId=88ed158e538fe, content=<a href='/topic/show?id=d1201843d5' target=_blank style='color:#2F92EE;'>#ACE抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1843, encryptionId=d1201843d5, topicName=ACE抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca217484051, createdName=huanbaofeng, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589331, encodeId=5aa115893316a, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=)]
2020-08-03 zhyy88

#阻滞剂#

78 0
[GetPortalCommentsPageByObjectIdResponse(id=2085838, encodeId=6f3f2085838f2, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Aug 03 18:25:18 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656005, encodeId=251a16560051c, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Jun 18 05:25:18 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852309, encodeId=5822185230916, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Sep 17 14:25:18 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995210, encodeId=1f65199521099, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Aug 02 17:25:18 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460174, encodeId=623714601e45a, content=<a href='/topic/show?id=34442e21d6' target=_blank style='color:#2F92EE;'>#ARBs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2721, encryptionId=34442e21d6, topicName=ARBs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b56256828, createdName=redcrab, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514758, encodeId=5fc71514e589a, content=<a href='/topic/show?id=ac3489e555e' target=_blank style='color:#2F92EE;'>#血管紧张素受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89755, encryptionId=ac3489e555e, topicName=血管紧张素受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56ce10676101, createdName=1249894fm76暂无昵称, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587538, encodeId=88ed158e538fe, content=<a href='/topic/show?id=d1201843d5' target=_blank style='color:#2F92EE;'>#ACE抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1843, encryptionId=d1201843d5, topicName=ACE抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca217484051, createdName=huanbaofeng, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589331, encodeId=5aa115893316a, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=)]
2020-06-18 shanyongle

#ACE#

70 0
[GetPortalCommentsPageByObjectIdResponse(id=2085838, encodeId=6f3f2085838f2, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Aug 03 18:25:18 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656005, encodeId=251a16560051c, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Jun 18 05:25:18 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852309, encodeId=5822185230916, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Sep 17 14:25:18 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995210, encodeId=1f65199521099, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Aug 02 17:25:18 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460174, encodeId=623714601e45a, content=<a href='/topic/show?id=34442e21d6' target=_blank style='color:#2F92EE;'>#ARBs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2721, encryptionId=34442e21d6, topicName=ARBs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b56256828, createdName=redcrab, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514758, encodeId=5fc71514e589a, content=<a href='/topic/show?id=ac3489e555e' target=_blank style='color:#2F92EE;'>#血管紧张素受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89755, encryptionId=ac3489e555e, topicName=血管紧张素受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56ce10676101, createdName=1249894fm76暂无昵称, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587538, encodeId=88ed158e538fe, content=<a href='/topic/show?id=d1201843d5' target=_blank style='color:#2F92EE;'>#ACE抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1843, encryptionId=d1201843d5, topicName=ACE抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca217484051, createdName=huanbaofeng, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589331, encodeId=5aa115893316a, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=)]
2020-09-17 jklm09

#抑制剂#

0 0
[GetPortalCommentsPageByObjectIdResponse(id=2085838, encodeId=6f3f2085838f2, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Aug 03 18:25:18 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656005, encodeId=251a16560051c, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Jun 18 05:25:18 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852309, encodeId=5822185230916, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Sep 17 14:25:18 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995210, encodeId=1f65199521099, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Aug 02 17:25:18 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460174, encodeId=623714601e45a, content=<a href='/topic/show?id=34442e21d6' target=_blank style='color:#2F92EE;'>#ARBs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2721, encryptionId=34442e21d6, topicName=ARBs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b56256828, createdName=redcrab, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514758, encodeId=5fc71514e589a, content=<a href='/topic/show?id=ac3489e555e' target=_blank style='color:#2F92EE;'>#血管紧张素受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89755, encryptionId=ac3489e555e, topicName=血管紧张素受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56ce10676101, createdName=1249894fm76暂无昵称, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587538, encodeId=88ed158e538fe, content=<a href='/topic/show?id=d1201843d5' target=_blank style='color:#2F92EE;'>#ACE抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1843, encryptionId=d1201843d5, topicName=ACE抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca217484051, createdName=huanbaofeng, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589331, encodeId=5aa115893316a, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=)]
2020-08-02 tulenzi

#受体阻滞剂#

83 0
[GetPortalCommentsPageByObjectIdResponse(id=2085838, encodeId=6f3f2085838f2, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Aug 03 18:25:18 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656005, encodeId=251a16560051c, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Jun 18 05:25:18 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852309, encodeId=5822185230916, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Sep 17 14:25:18 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995210, encodeId=1f65199521099, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Aug 02 17:25:18 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460174, encodeId=623714601e45a, content=<a href='/topic/show?id=34442e21d6' target=_blank style='color:#2F92EE;'>#ARBs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2721, encryptionId=34442e21d6, topicName=ARBs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b56256828, createdName=redcrab, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514758, encodeId=5fc71514e589a, content=<a href='/topic/show?id=ac3489e555e' target=_blank style='color:#2F92EE;'>#血管紧张素受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89755, encryptionId=ac3489e555e, topicName=血管紧张素受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56ce10676101, createdName=1249894fm76暂无昵称, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587538, encodeId=88ed158e538fe, content=<a href='/topic/show?id=d1201843d5' target=_blank style='color:#2F92EE;'>#ACE抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1843, encryptionId=d1201843d5, topicName=ACE抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca217484051, createdName=huanbaofeng, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589331, encodeId=5aa115893316a, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=)]
2020-03-26 redcrab

#ARBs#

90 0
[GetPortalCommentsPageByObjectIdResponse(id=2085838, encodeId=6f3f2085838f2, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Aug 03 18:25:18 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656005, encodeId=251a16560051c, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Jun 18 05:25:18 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852309, encodeId=5822185230916, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Sep 17 14:25:18 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995210, encodeId=1f65199521099, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Aug 02 17:25:18 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460174, encodeId=623714601e45a, content=<a href='/topic/show?id=34442e21d6' target=_blank style='color:#2F92EE;'>#ARBs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2721, encryptionId=34442e21d6, topicName=ARBs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b56256828, createdName=redcrab, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514758, encodeId=5fc71514e589a, content=<a href='/topic/show?id=ac3489e555e' target=_blank style='color:#2F92EE;'>#血管紧张素受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89755, encryptionId=ac3489e555e, topicName=血管紧张素受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56ce10676101, createdName=1249894fm76暂无昵称, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587538, encodeId=88ed158e538fe, content=<a href='/topic/show?id=d1201843d5' target=_blank style='color:#2F92EE;'>#ACE抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1843, encryptionId=d1201843d5, topicName=ACE抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca217484051, createdName=huanbaofeng, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589331, encodeId=5aa115893316a, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=)]
2020-03-26 1249894fm76暂无昵称

#血管紧张素受体阻滞剂#

87 0
[GetPortalCommentsPageByObjectIdResponse(id=2085838, encodeId=6f3f2085838f2, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Aug 03 18:25:18 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656005, encodeId=251a16560051c, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Jun 18 05:25:18 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852309, encodeId=5822185230916, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Sep 17 14:25:18 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995210, encodeId=1f65199521099, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Aug 02 17:25:18 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460174, encodeId=623714601e45a, content=<a href='/topic/show?id=34442e21d6' target=_blank style='color:#2F92EE;'>#ARBs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2721, encryptionId=34442e21d6, topicName=ARBs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b56256828, createdName=redcrab, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514758, encodeId=5fc71514e589a, content=<a href='/topic/show?id=ac3489e555e' target=_blank style='color:#2F92EE;'>#血管紧张素受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89755, encryptionId=ac3489e555e, topicName=血管紧张素受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56ce10676101, createdName=1249894fm76暂无昵称, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587538, encodeId=88ed158e538fe, content=<a href='/topic/show?id=d1201843d5' target=_blank style='color:#2F92EE;'>#ACE抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1843, encryptionId=d1201843d5, topicName=ACE抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca217484051, createdName=huanbaofeng, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589331, encodeId=5aa115893316a, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=)]
2020-03-26 huanbaofeng

#ACE抑制剂#

75 0
[GetPortalCommentsPageByObjectIdResponse(id=2085838, encodeId=6f3f2085838f2, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Aug 03 18:25:18 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656005, encodeId=251a16560051c, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Jun 18 05:25:18 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852309, encodeId=5822185230916, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Sep 17 14:25:18 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995210, encodeId=1f65199521099, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Aug 02 17:25:18 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460174, encodeId=623714601e45a, content=<a href='/topic/show?id=34442e21d6' target=_blank style='color:#2F92EE;'>#ARBs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2721, encryptionId=34442e21d6, topicName=ARBs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b56256828, createdName=redcrab, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514758, encodeId=5fc71514e589a, content=<a href='/topic/show?id=ac3489e555e' target=_blank style='color:#2F92EE;'>#血管紧张素受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89755, encryptionId=ac3489e555e, topicName=血管紧张素受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56ce10676101, createdName=1249894fm76暂无昵称, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587538, encodeId=88ed158e538fe, content=<a href='/topic/show?id=d1201843d5' target=_blank style='color:#2F92EE;'>#ACE抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1843, encryptionId=d1201843d5, topicName=ACE抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca217484051, createdName=huanbaofeng, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589331, encodeId=5aa115893316a, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Thu Mar 26 03:25:18 CST 2020, time=2020-03-26, status=1, ipAttribution=)]
2020-03-26 xiongliangxl

#血管紧张素#

74 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

心血管

ACE抑制剂和血管紧张素受体阻滞剂（ARBs）可能增加罹患COVID-19的风险

相关资讯

拓展阅读

科室

工具

服务